Lonsurf, an oral medication intended to treat patients with advanced colorectal cancer, was recently approved by the FDA.
The pill combines two drugs, trifluridine and tipiracil, and can be used for patients who are no longer responding to other therapies.
The efficacy and safety of Lonsurf were evaluated in an international, randomized, double-blind study involving 800 patients with previously treated metastatic colorectal cancer.
The efficacy and safety of Lonsurf were evaluated in an international, randomized, double-blind study involving 800 patients with previously treated metastatic colorectal cancer.
The FDA recommends that health care providers obtain complete blood counts prior to starting each treatment cycle of Lonsurf and monitor patients throughout treatment, as Lonsurf may cause a severe decrease in blood cell and platelet production.
